Kabra Drugs MD, chairman, board of directors and AGM
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹16.64.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹38 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 58,004
Kabra Drugs board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Managing directorNANJAPPAN ARAVIND
- ChairpersonANAND ANITHA
- Company Secretary and Compliance OfficerMonika Sanwal
6 directors4 independent2 executive
- NANJAPPAN ARAVIND · Managing directorExecutive · joined Aug 2024 · reappointed Sep 2024 · 1 listed board
- KUNIAMUTHUR NANJAPPAN ANANDExecutive · joined Jun 2022 · reappointed Sep 2022 · 1 listed board
- ANAND ANITHA · ChairpersonIndependent · joined Jul 2022 · reappointed Sep 2022 · 41 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- RITU TIWARIIndependent · joined Oct 2025 · reappointed Dec 2025 · 9 months as independent · 3 listed boards · 3 as independent · 1 committee seat
- NIKITA SINHAIndependent · joined Oct 2025 · reappointed Dec 2025 · 9 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 1 as chair
- MONAM KAPOORIndependent · joined Apr 2026 · 2 months as independent · 6 listed boards · 6 as independent · 4 committee seats, 2 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- B V ANATHA KUMAR, left 8 Oct 2025: Others
- ANANTHKUMAR SHILPA, left 8 Oct 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 29 May 20266 of 6 present4 independent · 22 days in between
- 6 May 20266 of 6 present4 independent · 14 days in between
- 21 Apr 20265 of 5 present3 independent · 44 days in between
- 7 Mar 20265 of 5 present3 independent · 21 days in between
2 earlier meetings
- 13 Feb 20265 of 5 present3 independent · 42 days in between
- 1 Jan 20265 of 5 present3 independent
Audit Committee
Chair NIKITA SINHA
ANAND ANITHA, KUNIAMUTHUR NANJAPPAN ANAND
- 29 May 20263 of 3 present3 independent · 104 days in between
- 13 Feb 20263 of 3 present3 independent
Nomination and remuneration committee
Chair RITU TIWARI
ANAND ANITHA, NIKITA SINHA
- 21 Apr 20263 of 3 present3 independent · 66 days in between
- 13 Feb 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair ANAND ANITHA
NIKITA SINHA, RITU TIWARI
- 13 Feb 20263 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- P P N And CompanyPeer-review certificate valid to Sep 2028
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Kabra Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Kabra Drugs share news and announcements
Annual general meeting, 30 Sep 2026
9,853 shareholders on the register on 23 Sep 2026; present: 0 promoters and 36 others; votes counted by CS JAY JAIN / JAY JAIN & ASSOCIATES.The company's voting result (opens in a new tab)
- To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended 31st March 2026, and the reports of the Board of Directors and Auditors thereonOrdinary99.87% for0.13% against
Against: other public 0.13%
Turnout: all 13.09% · other public 13.09%
- To appoint a director in place of Mr. Kuniamuthur Nanjappan Anand (DIN: 03230186) who retires by rotation, and being eligible, offers himself for re-appointmentOrdinary99.84% for0.16% against
Against: other public 0.16%
Turnout: all 10.31% · other public 10.31%
- TO APPOINT MS. MOONAM KAPOOR (DIN: 09278005), AS NON EXECUTIVE INDEPENDENT DIRECTORSpecial99.56% for0.44% against
Against: other public 0.44%
Turnout: all 13.09% · other public 13.09%
- TO APPOINT MRS. TWINKLE AGARWAL AS SECRETARIAL AUDITOR OF THE COMPANYSpecial99.82% for0.18% against
Against: other public 0.18%
Turnout: all 13.09% · other public 13.09%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states and its own uses differ by fifty times or more, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesFeb 2025 | – | Issue of 13628750 Equity Shares to Strategic Investors (being Non· Promoters) on Preferential allotment basis is being made for cash with the object of meeting the working capital requirements, Acquisition of Business,factory, office ,Machinary and general corporate purposes in order to support the future growth plan of the Company | – | – | No |